Shuvra Kanti Dey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shuvra Kanti Dey has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Nadim Sharif
Department of Microbiology, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh
34 shared publications Ali Azam Talukder
Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh
12 shared publicationsAfsana Khan
Department of Statistics, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh
10 shared publicationsAnowar Khasru Parvez
Department of Microbiology, Jahangirnagar University, Dhaka, Bangladesh
9 shared publicationsHiroshi Ushijima
Division of Microbiology, Department of Pathology and Microbiology, School of Medicine, Nihon University, Tokyo, Japan
8 shared publicationsFuad M. Alzahrani
Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia
7 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Structure-based computational screening and molecular dynamics reveal potential inhibitors of Norovirus VP1 and RdRp Proteins: an in-silico study
Norovirus is a major enteric pathogen with pandemic potential and disproportionately high mortality in low-income countries, particularly among young children. Despite its global health burden, no approved vaccine or specific antiviral therapy is currently available. In this study, we targeted two key viral proteins, viral protein 1 (VP1) and RNA-dependent RNA polymerase (RdRp). The workflow included protein modeling, structural stability assessment, molecular docking, molecular dynamics (MD) simulations, non-covalent interaction (NCI) analysis, protein contact atlas evaluation, and pharmacokinetic (ADME-Tox) profiling. Molecular docking results indicated strong binding affinities of selected phytochemicals—Zingiberol, Cardeonolide, Boeravinone B, β-Elemene, and Fisetin—toward both VP1 and RdRp, with binding energies ranging from − 7.8 to − 9.4 kcal/mol. MD simulations further demonstrated the structural stability of protein–ligand complexes, with stable RMSD values (~ 0.3 nm for RdRp and 0.3–0.5 nm for VP1) and only minor transient fluctuations observed in VP1. RMSF analysis revealed localized flexibility, while radius of gyration, hydrogen bonding patterns, and solvent-accessible surface area collectively confirmed overall conformational stability throughout the simulation period. Complementary protein contact atlas and NCI analyses supported the persistence and robustness of protein–ligand interactions, showing comparable or improved stability relative to reference antivirals ribavirin and nitazoxanide. Additionally, all selected compounds exhibited favorable drug-likeness and acceptable ADME-Tox properties. Collectively, these findings suggest that the identified phytochemicals may serve as promising antiviral candidates against norovirus, although further validation through in vitro and in vivo studies is required.
- 24 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessStructure-based computational screening and molecular dynamics reveal potential inhibitors of Norovirus VP1 and RdRp Proteins: an in-silico study
Norovirus is a major enteric pathogen with pandemic potential and disproportionately high mortality in low-income countries, particularly among young children. Despite its global health burden, no approved vaccine or specific antiviral therapy is currently available. In this study, we targeted two key viral proteins, viral protein 1 (VP1) and RNA-dependent RNA polymerase (RdRp). The workflow included protein modeling, structural stability assessment, molecular docking, molecular dynamics (MD) simulations, non-covalent interaction (NCI) analysis, protein contact atlas evaluation, and pharmacokinetic (ADME-Tox) profiling. Molecular docking results indicated strong binding affinities of selected phytochemicals—Zingiberol, Cardeonolide, Boeravinone B, β-Elemene, and Fisetin—toward both VP1 and RdRp, with binding energies ranging from − 7.8 to − 9.4 kcal/mol. MD simulations further demonstrated the structural stability of protein–ligand complexes, with stable RMSD values (~ 0.3 nm for RdRp and 0.3–0.5 nm for VP1) and only minor transient fluctuations observed in VP1. RMSF analysis revealed localized flexibility, while radius of gyration, hydrogen bonding patterns, and solvent-accessible surface area collectively confirmed overall conformational stability throughout the simulation period. Complementary protein contact atlas and NCI analyses supported the persistence and robustness of protein–ligand interactions, showing comparable or improved stability relative to reference antivirals ribavirin and nitazoxanide. Additionally, all selected compounds exhibited favorable drug-likeness and acceptable ADME-Tox properties. Collectively, these findings suggest that the identified phytochemicals may serve as promising antiviral candidates against norovirus, although further validation through in vitro and in vivo studies is required.
- Open Access
- 11 June 2026
- Published by Elsevier in New Microbes and New Infections
- Vol. 72, 101793
Spatiotemporal trends, evolving seasonality and symptoms of dengue in Bangladesh, 2019-2025
- 11 June 2026
- Published by Elsevier in New Microbes and New Infections
- Vol. 72, 101793
Open AccessSpatiotemporal trends, evolving seasonality and symptoms of dengue in Bangladesh, 2019-2025
- Open Access
- 26 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Emergence of human enteric adenovirus F41 among children with gastroenteritis in North-central Bangladesh, 2022–2024
Human adenovirus F-41 (HAdV-F41) is an emerging cause of pediatric gastroenteritis, but data from South Asia remain limited. We investigated the molecular epidemiology, clinical features, seasonality of adenovirus-associated gastroenteritis and feasibility of an immunochromatography (IC) kit among children under 5 in north-central Bangladesh during July 2022-June 2024. Fecal samples from 360 children with acute gastroenteritis were tested for viral and bacterial pathogens using PCR, sequencing, and phylogenetic analyses. HAdV was detected in 7% (25/360) of cases, which was the second most common virus after rotavirus. Most adenovirus-positive samples (76%, 19/25) were adenovirus F-41. Infected children, aged 12-35 months, exhibited more severe gastrointestinal symptoms, including dehydration and severe vomiting. Infections peaked during colder months and were correlated with temperature. Study strains were closely related with contemporary global adenovirus F-41 strains. A rapid immunochromatographic assay for HAdV demonstrated high agreement with PCR. These findings identify adenovirus F-41 as an emerging contributor to pediatric gastroenteritis in Bangladesh and highlight the need for enhanced surveillance.
- 26 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessEmergence of human enteric adenovirus F41 among children with gastroenteritis in North-central Bangladesh, 2022–2024
Human adenovirus F-41 (HAdV-F41) is an emerging cause of pediatric gastroenteritis, but data from South Asia remain limited. We investigated the molecular epidemiology, clinical features, seasonality of adenovirus-associated gastroenteritis and feasibility of an immunochromatography (IC) kit among children under 5 in north-central Bangladesh during July 2022-June 2024. Fecal samples from 360 children with acute gastroenteritis were tested for viral and bacterial pathogens using PCR, sequencing, and phylogenetic analyses. HAdV was detected in 7% (25/360) of cases, which was the second most common virus after rotavirus. Most adenovirus-positive samples (76%, 19/25) were adenovirus F-41. Infected children, aged 12-35 months, exhibited more severe gastrointestinal symptoms, including dehydration and severe vomiting. Infections peaked during colder months and were correlated with temperature. Study strains were closely related with contemporary global adenovirus F-41 strains. A rapid immunochromatographic assay for HAdV demonstrated high agreement with PCR. These findings identify adenovirus F-41 as an emerging contributor to pediatric gastroenteritis in Bangladesh and highlight the need for enhanced surveillance.
- Open Access
- 27 January 2026
- Published by Springer Nature in In Silico Pharmacology
- Vol. 14 (1)
In silico prediction, molecular docking and simulation of natural flavonoid apigenin and xanthoangelol E against human metapneumovirus
The online version contains supplementary material available at 10.1007/s40203-025-00539-7.
- 27 January 2026
- Published by Springer Nature in In Silico Pharmacology
- Vol. 14 (1)
Open AccessIn silico prediction, molecular docking and simulation of natural flavonoid apigenin and xanthoangelol E against human metapneumovirus
The online version contains supplementary material available at 10.1007/s40203-025-00539-7.
- Open Access
- 5 January 2026
- Published by Springer Nature in Research Square
Structure-based computational screening and molecular dynamics reveal potential inhibitors of Norovirus VP1 and RdRp Proteins: an in-silico study
Norovirus is recognized as a pathogen with pandemic potential, exhibiting a higher fatality rate in low-income countries, particularly affecting young children. Currently, vaccine or specific antiviral treatment for norovirus is lacking. For evaluating antiviral compounds, this study was conducted by targeting viral protein 1 (VP1) and RNA-dependent RNA polymerase (RdRP) proteins through in silico approach, which included modeling protein, assessment stability, molecular docking, molecular simulation, non-covalent interaction (NCI) analysis, and pharmacokinetic profiling. Higher binding affinity revealed by molecular docking (-7.8 kcal/mol to -9.4 kcal/mol) for the ligands Zingiberol, Cardeonolide, Boeravinone B, Beta-Elemene, and Fisetin with VP1 and RdRp. The molecular dynamic simulation and subsequent analyses demonstrated significantly expected stable docked complexes of the protein-ligand in comparison to the ribavirin antiviral drug. Furthermore, these ligands exhibited acceptable drug-likeness and ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) profiles. This study initially suggests that these compounds have potentiality as antiviral candidates, warranting wet lab experiment to be considered for norovirus infection.
- 5 January 2026
- Published by Springer Nature in Research Square
Open AccessStructure-based computational screening and molecular dynamics reveal potential inhibitors of Norovirus VP1 and RdRp Proteins: an in-silico study
Norovirus is recognized as a pathogen with pandemic potential, exhibiting a higher fatality rate in low-income countries, particularly affecting young children. Currently, vaccine or specific antiviral treatment for norovirus is lacking. For evaluating antiviral compounds, this study was conducted by targeting viral protein 1 (VP1) and RNA-dependent RNA polymerase (RdRP) proteins through in silico approach, which included modeling protein, assessment stability, molecular docking, molecular simulation, non-covalent interaction (NCI) analysis, and pharmacokinetic profiling. Higher binding affinity revealed by molecular docking (-7.8 kcal/mol to -9.4 kcal/mol) for the ligands Zingiberol, Cardeonolide, Boeravinone B, Beta-Elemene, and Fisetin with VP1 and RdRp. The molecular dynamic simulation and subsequent analyses demonstrated significantly expected stable docked complexes of the protein-ligand in comparison to the ribavirin antiviral drug. Furthermore, these ligands exhibited acceptable drug-likeness and ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) profiles. This study initially suggests that these compounds have potentiality as antiviral candidates, warranting wet lab experiment to be considered for norovirus infection.
- Open Access
- 22 September 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (9) , e71300
Trends of Human Metapneumovirus Outbreaks in Bangladesh: Probable Risks and Preventive Strategies
Background and Aims: Human metapneumovirus (hMPV) is one of the major pathogens associated with respiratory tract infection and is a rising concern for people with compromised immunity worldwide. Amid the global concern about the increased incidence of hMPV, we found a significant lack of studies on the epidemiology of this virus in Bangladesh. Methods: In this study, we integrated the previous reports of hMPV in Bangladesh and characterized the cases. Results: We found that hMPV has been continuously circulating since 2000 among the residents of Bangladesh. The prevalence varied from 3.9% to 33% among children aged below 5 years. The cases were reported from Dhaka, Chittagong, Cumilla, Bogura, and Barishal. Among the symptoms, fever (80%–100%), cough (85%–100%), tachypnea (70%–100%), runny nose (80%–97%), and difficulty breathing (70%–85%) were the most common. Conclusion: This is the first integrated study of hMPV outbreak characterization in Bangladesh.
- 22 September 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (9) , e71300
Open AccessTrends of Human Metapneumovirus Outbreaks in Bangladesh: Probable Risks and Preventive Strategies
Background and Aims: Human metapneumovirus (hMPV) is one of the major pathogens associated with respiratory tract infection and is a rising concern for people with compromised immunity worldwide. Amid the global concern about the increased incidence of hMPV, we found a significant lack of studies on the epidemiology of this virus in Bangladesh. Methods: In this study, we integrated the previous reports of hMPV in Bangladesh and characterized the cases. Results: We found that hMPV has been continuously circulating since 2000 among the residents of Bangladesh. The prevalence varied from 3.9% to 33% among children aged below 5 years. The cases were reported from Dhaka, Chittagong, Cumilla, Bogura, and Barishal. Among the symptoms, fever (80%–100%), cough (85%–100%), tachypnea (70%–100%), runny nose (80%–97%), and difficulty breathing (70%–85%) were the most common. Conclusion: This is the first integrated study of hMPV outbreak characterization in Bangladesh.
- Open Access
- 18 June 2025
- Published by Springer Nature in Research Square
Natural flavonoid apigenin and xanthoangelol E are potent antivirals against human metapneumovirus: an in-silico study
Human metapneumovirus (hMPV) is one of the potential pandemic pathogens, and it is a concern for elderly subjects and immunocompromised patients. There is no vaccine or specific antiviral available for hMPV. We conducted an in-silico study to develop antivirals against human metapneumovirus. Our methodology included protein modeling, stability assessment, molecular docking, molecular simulation, analysis of non-covalent interactions, bioavailability, carcinogenicity, and pharmacokinetic profiling. We pinpointed four plant-derived bio-compounds as antiviral candidates. Among the compounds, apigenin showed the highest binding affinity, with values of -8.0 kcal/mol for the hMPV-F protein and -7.6 kcal/mol for the hMPV-N protein. Molecular dynamic simulations and further analyses confirmed that the protein-ligand docked complexes exhibited significantly acceptable stability compared to two standard antiviral drugs. Additionally, these four compounds yielded satisfactory outcomes in bioavailability, drug-likeness, and ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) and STopTox analyses. This study highlights the highest potential of apigenin and xanthoangelol E as effective antivirals, underscoring the necessity for preclinical and clinical trials and wet-lab evaluation to consider them as treatments for human metapneumovirus infection.
- 18 June 2025
- Published by Springer Nature in Research Square
Open AccessNatural flavonoid apigenin and xanthoangelol E are potent antivirals against human metapneumovirus: an in-silico study
Human metapneumovirus (hMPV) is one of the potential pandemic pathogens, and it is a concern for elderly subjects and immunocompromised patients. There is no vaccine or specific antiviral available for hMPV. We conducted an in-silico study to develop antivirals against human metapneumovirus. Our methodology included protein modeling, stability assessment, molecular docking, molecular simulation, analysis of non-covalent interactions, bioavailability, carcinogenicity, and pharmacokinetic profiling. We pinpointed four plant-derived bio-compounds as antiviral candidates. Among the compounds, apigenin showed the highest binding affinity, with values of -8.0 kcal/mol for the hMPV-F protein and -7.6 kcal/mol for the hMPV-N protein. Molecular dynamic simulations and further analyses confirmed that the protein-ligand docked complexes exhibited significantly acceptable stability compared to two standard antiviral drugs. Additionally, these four compounds yielded satisfactory outcomes in bioavailability, drug-likeness, and ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) and STopTox analyses. This study highlights the highest potential of apigenin and xanthoangelol E as effective antivirals, underscoring the necessity for preclinical and clinical trials and wet-lab evaluation to consider them as treatments for human metapneumovirus infection.
- Open Access
- 25 March 2025
- Published by Springer Nature in Research Square
In silico prediction, molecular docking and simulation of antiviral compounds against major proteins of Nipah virus
Nipah virus (NiV) is one of the pandemic potential pathogens with a higher case fatality rate of around 80%. There is no vaccine or specific antiviral available for NiV. We performed this study to evaluate antiviral compounds against NiV-G, NiV-F, NiV-M, NiV-P, NiV-N, and NiV-W proteins through in silico analysis including protein modeling, stability checking, molecular docking, molecular simulation, non-covalent interactions, bioavailability, and pharmacokinetics profiling. Molecular docking provided higher binding affinity (-9.0 kcal/mol to -10.4 kcal/mol) among ligand CID71721532 (PubChem ID) and NiV-G, NiV-M, NiV-F, and NiV-P proteins. Another ligand CID11395956 (PubChem ID) demonstrated the lowest binding energies at -8.7 kcal/mol and -9.5 kcal/mol for NiV-W and Niv-N, respectively. The molecular dynamic simulation and further analysis provided significantly acceptable stability of the protein-ligand docked complexes compared to the antiviral favipiravir. Furthermore, these two compounds provided acceptable values in bioavailability, drug-likeness, ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) and STopTox analyses. This study suggests the potentiality of these compounds as suitable antivirals which need preclinical and clinical trials and wet lab evaluation to be considered as drugs for Nipah virus infection.
- 25 March 2025
- Published by Springer Nature in Research Square
Open AccessIn silico prediction, molecular docking and simulation of antiviral compounds against major proteins of Nipah virus
Nipah virus (NiV) is one of the pandemic potential pathogens with a higher case fatality rate of around 80%. There is no vaccine or specific antiviral available for NiV. We performed this study to evaluate antiviral compounds against NiV-G, NiV-F, NiV-M, NiV-P, NiV-N, and NiV-W proteins through in silico analysis including protein modeling, stability checking, molecular docking, molecular simulation, non-covalent interactions, bioavailability, and pharmacokinetics profiling. Molecular docking provided higher binding affinity (-9.0 kcal/mol to -10.4 kcal/mol) among ligand CID71721532 (PubChem ID) and NiV-G, NiV-M, NiV-F, and NiV-P proteins. Another ligand CID11395956 (PubChem ID) demonstrated the lowest binding energies at -8.7 kcal/mol and -9.5 kcal/mol for NiV-W and Niv-N, respectively. The molecular dynamic simulation and further analysis provided significantly acceptable stability of the protein-ligand docked complexes compared to the antiviral favipiravir. Furthermore, these two compounds provided acceptable values in bioavailability, drug-likeness, ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) and STopTox analyses. This study suggests the potentiality of these compounds as suitable antivirals which need preclinical and clinical trials and wet lab evaluation to be considered as drugs for Nipah virus infection.
- Open Access
- 26 February 2025
- Published by Springer Nature in npj Clean Water
- Vol. 8 (1) , 1-15
Antimicrobial resistant enteric bacteria are widely distributed among environmental water sources in Dhaka, Bangladesh
- 26 February 2025
- Published by Springer Nature in npj Clean Water
- Vol. 8 (1) , 1-15
Open AccessAntimicrobial resistant enteric bacteria are widely distributed among environmental water sources in Dhaka, Bangladesh
- Open Access
- 25 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf039
Clinical Epidemiology of Dengue and COVID-19 Co-infection Among the Residents in Dhaka, Bangladesh, 2021–2023: A Cross-sectional Study
Background: Co-infection of dengue and COVID-19 has increased the health burden worldwide. We found a significant knowledge gap in epidemiology and risk factors of co-infection in Bangladesh. Methods: This study included 2458 participants from Dhaka city from 1 December 2021 to November 30 2023. We performed the Kruskal-Wallis test and χ2 test. Multivariable logistic regression was also performed. Results: Co-infection of dengue and COVID-19 was found among 31% of the participants. Coprevalence of dengue and COVID-19 was found in higher frequency in Jatrabari (14%) and Motijhil (11%). Severe (65%, P = .001) and very severe (78%, P = .005) symptoms were prevalent among the participants aged >50 years. Long-term illness was prevalent among the participants with co-infection (35%; 95% confidence interval [CI], 33–36) and COVID-19 (28%; 95% CI, 26–30). Co-infected participants had a higher frequency of heart damage (31.6%, P = .005), brain fog (22%, P = .03), and kidney damage (49.3%, P = .001). Fever (100%) was the most prevalent symptom followed by weakness (89.6%), chills (82.4%), fatigue (81.4%), headache (80.6%), feeling thirsty (76.3%), myalgia (75%), pressure in the chest (69.1%), and shortness of breath (68.3%), respectively. Area of residence (odds ratio [OR], 2.26; 95% CI, 1.96–2.49, P = .01), number of family members (OR, 1.45; 95% CI ,1.08–1.87; P <.001), and population density (OR, 2.43; 95% CI, 2.15–3.01; P = .001) were associated with higher odds of co-infection. We found that coinfected participants had a 4 times higher risk of developing severe health conditions (OR, 4.22; 95% CI, 4.11–4.67; P = .02). Conclusions: This is one of the early epidemiologic studies of co-infection of dengue and COVID-19 in Bangladesh.
- 25 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf039
Open AccessClinical Epidemiology of Dengue and COVID-19 Co-infection Among the Residents in Dhaka, Bangladesh, 2021–2023: A Cross-sectional Study
Background: Co-infection of dengue and COVID-19 has increased the health burden worldwide. We found a significant knowledge gap in epidemiology and risk factors of co-infection in Bangladesh. Methods: This study included 2458 participants from Dhaka city from 1 December 2021 to November 30 2023. We performed the Kruskal-Wallis test and χ2 test. Multivariable logistic regression was also performed. Results: Co-infection of dengue and COVID-19 was found among 31% of the participants. Coprevalence of dengue and COVID-19 was found in higher frequency in Jatrabari (14%) and Motijhil (11%). Severe (65%, P = .001) and very severe (78%, P = .005) symptoms were prevalent among the participants aged >50 years. Long-term illness was prevalent among the participants with co-infection (35%; 95% confidence interval [CI], 33–36) and COVID-19 (28%; 95% CI, 26–30). Co-infected participants had a higher frequency of heart damage (31.6%, P = .005), brain fog (22%, P = .03), and kidney damage (49.3%, P = .001). Fever (100%) was the most prevalent symptom followed by weakness (89.6%), chills (82.4%), fatigue (81.4%), headache (80.6%), feeling thirsty (76.3%), myalgia (75%), pressure in the chest (69.1%), and shortness of breath (68.3%), respectively. Area of residence (odds ratio [OR], 2.26; 95% CI, 1.96–2.49, P = .01), number of family members (OR, 1.45; 95% CI ,1.08–1.87; P <.001), and population density (OR, 2.43; 95% CI, 2.15–3.01; P = .001) were associated with higher odds of co-infection. We found that coinfected participants had a 4 times higher risk of developing severe health conditions (OR, 4.22; 95% CI, 4.11–4.67; P = .02). Conclusions: This is one of the early epidemiologic studies of co-infection of dengue and COVID-19 in Bangladesh.